Example: Heart Attack

Search clinical trials for: Freund's Adjuvant

Total 86 results

NCT02200718

Not yet recruiting

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

Conditions: Multiple Sclerosis
NCT02149706

Not yet recruiting

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Conditions: Multiple Sclerosis
NCT00001703

Terminated

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

Conditions: Renal Cell Carcinoma
NCT00381875

Completed

Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV

Conditions: Nonneoplastic Condition
NCT00104780

Unknown status

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Conditions: Lung Cancer
NCT00030602

Completed

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Conditions: Prostate Cancer
NCT00066729

Completed

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
NCT00109811

Completed

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Conditions: Adenocarcinoma of the Prostate; Recurrent Prostate Cancer
NCT00001439

Completed

A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant

Conditions: Melanoma
NCT00705640

Completed

Vaccine Therapy in Treating Patients With Advanced Melanoma

Conditions: Intraocular Melanoma; Malignant Conjunctival Neoplasm; Melanoma (Skin)
NCT03879694

Recruiting

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Conditions: Lung Atypical Carcinoid Tumor; Lung Typical Carcinoid Tumor; Metastatic Pancreatic Neuroendocrine Tumor
NCT00002359

Completed

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

Conditions: HIV Infections
NCT00513578

Unknown status

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Conditions: Myelodysplastic Syndromes
NCT00089206

Completed

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Conditions: Intraocular Melanoma; Melanoma (Skin)
NCT00089193

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Conditions: Melanoma (Skin)
NCT00079157

Completed

Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer

Conditions: Breast Cancer
NCT00012246

Terminated

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

Conditions: Colorectal Cancer; Esophageal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Pancreatic Cancer; Small Intestine Cancer
NCT00077532

Completed

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

Conditions: Melanoma (Skin)
NCT00032045

Completed

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Conditions: Intraocular Melanoma; Melanoma (Skin)
NCT00022438

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment

Conditions: Melanoma (Skin)
NCT00021164

Completed

Vaccine Therapy in Treating Patients With Metastatic Cancer

Conditions: Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific
NCT00072085

Completed

Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma

Conditions: Melanoma (Skin)
NCT00019487

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Conditions: Melanoma (Skin)
NCT00003568

Completed

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Conditions: Melanoma (Skin)
NCT00085189

Completed

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Extraocular Extension Melanoma; Iris Melanoma; Metastatic Intraocular Melanoma; Mucosal Melanoma; Recurrent Intraocular Melanoma; Recurrent Melanoma; Stage IIC Melanoma; Stage IIIA Intraocular Melanoma; Stage IIIA Melanoma; Stage IIIB Intraocular Melanoma; Stage IIIB Melanoma; Stage IIIC Intraocular Melanoma; Stage IIIC Melanoma; Stage IV Intraocular Melanoma; Stage IV Melanoma